Orgovyx(relugolix) is an oral GnRH receptor antagonist used for advanced prostate cancer. Patients with severe hepatic impairment and pregnant or breastfeeding women are special risk populations and must be clearly evaluated before medication.

I. Patients with Severe Hepatic Impairment

1.Contraindication

Orgovyx is contraindicated in patients with severe hepatic impairment(Child-Pugh Class C). Drug exposure may be significantly increased in such patients, and the risk is uncontrollable.

2.Caution in Moderate Impairment

Patients with moderate hepatic impairment require close monitoring of liver function and adverse reactions; the decision is made by the doctor after weighing benefits and risks.

3.Pretreatment Evaluation

Liver function should be tested before medication to establish baseline levels; during treatment, regularly recheck indicators such as transaminases and bilirubin.

4.Signs of Liver Injury

Seek medical attention immediately if worsened fatigue, decreased appetite, yellowing of the skin or whites of the eyes, dark urine, or right upper abdominal discomfort occurs.

5.Drug Interactions

Avoid concomitant use with drugs that may aggravate liver injury or affect drug metabolism; consult a doctor or pharmacist before combining medications.

II. Information for Pregnant Women

1.Reason for Contraindication

Orgovyx can suppress the sex hormone axis and has embryo-fetal toxicity potential; it is contraindicated in pregnant women.

2.Pregnancy Testing

Women of childbearing potential should confirm pregnancy status before starting treatment; effective contraception should be used during treatment and for a period after discontinuation.

3.Management of Accidental Exposure

If accidentally exposed to this product during pregnancy, inform the doctor immediately for pregnancy risk assessment and obstetric follow-up; do not handle it on your own.

4.Pregnancy of a Male Patient's Partner

If a male patient's partner becomes pregnant during treatment, inform the doctor to assess potential effects.

III. Information for Breastfeeding Patients

1.Breastfeeding Not Recommended

There are no data on whether Orgovyx is secreted into human milk; breastfeeding women should not use this product. If it must be used due to the condition, breastfeeding should be stopped.

2.Potential Risks to the Breastfed Infant

The drug may affect the development of the infant's sex hormone axis through breast milk; due to the lack of safety data, breastfeeding should not be risked.

3.Conflict Between Contraception and Breastfeeding

Contraception is required during treatment; if already pregnant or planning to breastfeed, discuss alternative treatment options with the doctor in advance.

4.Breastfeeding After Discontinuation

The timing for resuming breastfeeding after discontinuation is unclear; consult the doctor and decide after considering drug clearance and disease assessment.

5.Common Principles

The above populations should fully inform the doctor of their liver function, pregnancy, and breastfeeding status before medication, strictly follow medical advice, and not use or stop medication on their own.